About Relacorilant
About Relacorilant
Relacorilant, an oral medication, is a selective glucocorticoid receptor (GR) antagonist that modulates cortisol activity by binding to the GR, but not to other hormone receptors in the body. In addition to ovarian cancer, Corcept is investigating Relacorilant in several other serious diseases, including endogenous hypercortisolism (Cushing's syndrome) and prostate cancer. Relacorilant is proprietary to Corcept and is protected by patents on its composition, use and other patents. It has been approved by the FDA and the European Commission (EC) for the treatment of hypercortisolism and by the EC for the treatment of ovarian cancer.
About platinum-resistant ovarian cancer
Ovarian cancer is the fifth leading cause of cancer death in women. Patients whose disease recurs less than six months after platinum-containing therapy have "platinum-resistant" disease. There are few treatment options for these women. The median overall survival after a recurrence is around 12 months with monochemotherapy. Every year, around 20,000 women with platinum-resistant disease are able to start a new therapy.the United States, with at least the same number inEurope.
